Oragenics, Inc(NYSE MKT:OGEN) 
Oragenics, Inc. develops antibiotics for infectious diseases in the United States. Its lead product candidate under development is OG716, an antibiotic for the treatment of Clostridium difficile. The company also engages in the development and commercialization of Terra CoV-2, a vaccine product cand...
Website: http://www.oragenics.com
Founded: 1996
Full Time Employees: 7
Sector: Healthcare
Industry: Biotechnology
The information provided in this report is taken from www.sec.gov. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Day
Week
Month
Date 2025-04-04
P
O 5.41
H 6.01
L 5.41
C 5.71
V 692,423
10EMA 5.71
20EMA 5.71
60EMA 5.71
120EMA 5.71
250EMA 5.71